| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cyclin-H, MO15-associated protein, p34, p37, CCNH |
| Entrez GeneID | 902 |
| WB Predicted band size | 37.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CCNH antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 269-299 amino acids from the C-terminal region of human CCNH. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4篇关于CCNH抗体的参考文献示例(内容基于领域内常见研究方向，部分信息可能需核实)：
---
1. **文献名称**：*Cyclin H expression and CDK-activating kinase activity in transcription regulation*
**作者**：Holmes, J.K., et al.
**摘要**：本研究利用特异性CCNH抗体通过Western blot和免疫沉淀技术，验证了Cyclin H与CDK7在调控RNA聚合酶II磷酸化中的作用，揭示了其在转录起始中的分子机制。
2. **文献名称**：*CCNH antibody-based profiling in non-small cell lung cancer*
**作者**：Zhang, Y., et al.
**摘要**：通过CCNH抗体的免疫组化(IHC)分析，发现Cyclin H在肺癌组织中高表达，并与患者预后不良相关，提示其作为潜在肿瘤标志物的价值。
3. **文献名称**：*Structural analysis of the CDK-activating kinase complex using CCNH-specific antibodies*
**作者**：Lee, S., et al.
**摘要**：采用CCNH抗体进行免疫荧光共定位和蛋白质复合物纯化，阐明了Cyclin H在CDK激活激酶复合体中的空间构象及其与底物结合的关键结构域。
4. **文献名称**：*Functional screening of Cyclin H antibody in CRISPR-edited cell lines*
**作者**：Fisher, R.P., et al.
**摘要**：通过CRISPR技术构建CCNH敲除细胞系，结合特异性抗体验证蛋白缺失，证实Cyclin H在细胞周期检查点和DNA损伤修复中的双重功能。
---
注：以上文献为示例，实际引用时建议通过PubMed或Google Scholar以关键词“CCNH antibody”或“Cyclin H antibody”检索最新研究。
The CCNH antibody is a crucial tool for studying cyclin H, a regulatory protein involved in cell cycle control and transcription. Cyclin H, encoded by the CCNH gene, forms a complex with cyclin-dependent kinase 7 (CDK7) and MAT1 to create the CDK-activating kinase (CAK) complex. This complex plays dual roles: it regulates cell cycle progression by phosphorylating CDKs (e.g., CDK1. CDK2. CDK4) to activate their kinase activity, and it participates in transcription by phosphorylating the C-terminal domain of RNA polymerase II. Dysregulation of cyclin H has been linked to cancers, neurodegenerative disorders, and developmental defects.
CCNH antibodies are widely used in research to detect cyclin H expression, localization, and interactions in various biological contexts. They enable techniques like Western blotting, immunofluorescence, and immunoprecipitation, helping to elucidate cyclin H's role in diseases and normal physiology. For example, studies using these antibodies have revealed CAK complex abnormalities in tumorigenesis and responses to CDK-targeted therapies. Both polyclonal and monoclonal CCNH antibodies are available, with validation often including knockout cell line controls to ensure specificity. Their applications extend to drug development, particularly in testing CDK inhibitors for cancer treatment. As cyclin H's functions in DNA repair and transcriptional stress responses gain attention, CCNH antibodies remain vital for advancing mechanistic and therapeutic research.
×
